RESEARCH RETROSOPECTIVE: Looking to nature to treat disease

This article is part of a monthly series celebrating research breakthroughs and successes at Brock University over the past 60 years. To read other stories in the series, visit The Brock News.

For most people, the Madagascar periwinkle makes a lovely addition to a home garden. For Vincenzo De Luca, the pink-flowered plant is a powerful weapon against cancer.

When De Luca became Brock University’s first Canada Research Chair (CRC) in 2001, he was on a mission to explore how vinblastine, a plant toxin in the Madagascar periwinkle that has been shown to stop cancer cell division, could be harnessed to treat the disease.

The then-Tier 1 Canada Research Chair in Plant Biotechnology and his team identified up to 40 genes involved in the production of vinblastine, and he says biologists have now transferred his genetic pathway — a sequential series of steps that genes control to bring about a certain result — to yeast, which forms a base ingredient for numerous medicines.

“Researchers all over the world are now using genomics to identify related genes in thousands of other plant species,” says the Professor Emeritus of Biological Sciences. They don’t have to start where we started — from the beginning.”

De Luca’s work, and CRC appointment, helped shape a new direction in Brock research focused on developing treatments for human disease.

Prior to De Luca’s arrival, then-Associate Professor of Chemistry James McNulty had been studying an anti-cancer alkaloid called pancratistatin found in some bulbs of the Amaryllis family of plants. Alkaloids are naturally occurring chemical compounds involved in many physiological processes.

Because it occurs in extremely low concentrations in the bulbs, McNulty and his team were also studying how to create a chemical compound similar to pancratistatin.

In 2003, McNulty made the move to McMaster University as the late Tomáš Hudlický, one of North America’s top organic chemists, joined Brock to became Tier 1 CRC in Organic Synthesis and Biocatalysis.

In 2017, Hudlický and his team, which included McNulty, published breakthrough research testing out a pancratistatin-like compound Hudlický created.

The team found his compound killed cancer cells in 20 different types of cancer while leaving healthy cells intact.

Hudlický patented several variations of his compound and also created synthetic versions of morphine and drugs similar to the influenza drug Tamiflu.

More recent drug development research at Brock has focused on looking inside the human body for answers.

Professor of Health Sciences Newman Sze has come up with a groundbreaking immunotherapy therapy that could be a future drug to clear up damaged proteins associated with aging and age-related diseases.

He and his team engineered an antibody stimulating the immune system to clear out proteins in tissues that had been damaged by isoDGR, an age-related process that triggers chronic inflammation and tissue degeneration.

Uncontrolled chronic inflammation, in turn, can lead to conditions such as cardiovascular disease, cancer, Type 2 diabetes, arthritis and Alzheimer’s disease.

Sze, the Tier 1 CRC in Mechanisms of Health and Disease, says his work offers hope for treating age-related diseases “in the natural way.”

“Our immune system is designed to protect and repair the body by addressing damage and threats,” he says. “By engineering specific antibodies to target damaged proteins, we’re enhancing its ability to do what it does best, heal the body by itself.”

Other leading-edge drug development research includes:

  • Associate Professor of Computer Science and Biological Sciences Yifeng Li’s use of artificial intelligence (AI) and machine learning to develop, or refine, drugs to treat cancer and other diseases and reduce the drugs’ side effects. The CRC in Machine Learning for Biomedical Data Science and his team recently discovered how AI can better create an RNA drug to prevent the SARS-CoV-2 virus — responsible for COVID-19 — from entering human cells.
  • Associate Professor of Kinesiology Val Fajardo’s collaboration with a U.K.-based company to refine a drug treating Duchenne muscular dystrophy (DMD) by suppressing an enzyme called GSK3 that leads to muscle wasting and declines in heart and brain function if overactivated. Some of their findings were recently published in Nature Communications. Fajardo holds the CRC in Tissue Re-modelling and Plasticity throughout the Lifespan.
  • Professor of Health Sciences Evangelia Tsiani’s discoveries indicating rosemary extract and carnosic acid, found within the herb rosemary,inhibit the growth of lung and prostate cancer cells, which could lead to possible new chemotherapy drugs.

Read more stories in: Applied Health Sciences, Digital Displays, Featured, Mathematics and Science, News, Research
Tagged with: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,